Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 3Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 6Sarcoma 1Gynecologic 1

Conditions

Ovarian Neoplasms 60Breast Neoplasms 21Neoplasms 19Fallopian Tube Neoplasms 16Prostatic Neoplasms 15Neoplasm Metastasis 9Pancreatic Neoplasms 8Endometrial Neoplasms 8Glioblastoma 7Triple Negative Breast Neoplasms 6Lung Neoplasms 5Carcinoma, Ovarian Epithelial 5Small Cell Lung Carcinoma 4Glioma 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Mesothelioma 3Melanoma 3Head and Neck Neoplasms 3Cystadenocarcinoma, Serous 3Cholangiocarcinoma 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Urogenital Neoplasms 2Stomach Neoplasms 2Solid Tumor 2Sarcoma 2Prostatic Neoplasms, Castration-Resistant 2Ovarian Diseases 2Mesothelioma, Malignant 2

Interventions

pembrolizumab 160Carboplatin 143Paclitaxel 125Cyclophosphamide 93130-nm albumin-bound paclitaxel 66Capecitabine 63Gemcitabine 54Doxorubicin 49Albumin-Bound Paclitaxel 45Taxes 42atezolizumab 40Cisplatin 37Nivolumab 34sacituzumab govitecan 32olaparib 32Epirubicin 32Docetaxel 28eribulin 27Specimen Handling 26Bevacizumab 26durvalumab 25camrelizumab 23Drug Therapy 22Biopsy 22Magnetic Resonance Spectroscopy 21toripalimab 18Radiotherapy 17spartalizumab 16Everolimus 15fludarabine 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × Triple Negative Breast Neoplasms × niraparib × Clear all
NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04837209 2025-10-01

NADiR

Massachusetts General Hospital

Phase 2 Active not recruiting
32 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03945721 2025-09-29

UNITY

Massachusetts General Hospital

Phase 1 Active not recruiting
21 enrolled
Breast

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT04915755 2025-07-16

ZEST

GlaxoSmithKline

Phase 3 Active not recruiting
40 enrolled 13 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02657889 2022-12-01

TOPACIO

Tesaro, Inc.

Phase 1/2 Completed
122 enrolled 29 charts
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT05461690 2022-07-18

Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency

Zhejiang Cancer Hospital

Phase 2 Unknown
50 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡